Pharmaceutical company Takeda Russia opened a new full-cycle production line for an orphan drug used to treat patients with multiple myeloma in the Novoselki Industrial Park in Yaroslavl.

The plant has become the second in the world where this drug is produced. 590 million roubles were invested in the launch of the plant.

Currently, multiple myeloma is considered an incurable disease and accounts for 1% of all malignant tumors and 13% in the structure of tumor diseases of hematopoietic and lymphatic tissues. The incidence of such cancer in our country is two cases per 100 thousand people.

According to the company's press service, the launch of the company will make it possible to satisfy the demand for the orphan drug in Russia and the countries of the Eurasian Economic Union. This means that more people facing this disease will be able to get the necessary therapy.

The drug received registration in Russia in 2017, a year later it was brought to the domestic market and given the status of orphan drug. In April this year, the commission of the Ministry of Health recommended to include the drug in the federal program of high-cost nosologies.

Made in Russia // Made in Russia

Author: Ksenia Gustova